Sage Therapeutics, Inc. (NASDAQ:SAGE) Receives Consensus Rating of “Hold” from Brokerages

Sage Therapeutics, Inc. (NASDAQ:SAGE) has been given an average rating of “Hold” by the twenty brokerages that are covering the stock, Marketbeat reports. Two analysts have rated the stock with a sell recommendation, sixteen have given a hold recommendation and two have issued a buy recommendation on the company. The average twelve-month target price among analysts that have covered the stock in the last year is $11.53.

A number of analysts recently issued reports on SAGE shares. TD Cowen lowered their target price on Sage Therapeutics from $10.00 to $9.00 and set a “hold” rating for the company in a research note on Thursday, November 21st. Needham & Company LLC restated a “hold” rating on shares of Sage Therapeutics in a report on Wednesday, November 20th. Stifel Nicolaus reduced their target price on shares of Sage Therapeutics from $10.00 to $6.00 and set a “hold” rating for the company in a research note on Monday, December 16th. HC Wainwright reissued a “neutral” rating and issued a $14.00 price target on shares of Sage Therapeutics in a research note on Wednesday, November 20th. Finally, StockNews.com downgraded Sage Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, October 31st.

Sage Therapeutics Stock Performance

Shares of NASDAQ SAGE opened at $5.48 on Wednesday. Sage Therapeutics has a 52-week low of $4.62 and a 52-week high of $28.26. The stock has a market cap of $335.23 million, a P/E ratio of -0.98 and a beta of 0.87. The firm has a 50 day moving average price of $6.04 and a 200 day moving average price of $8.10.

Sage Therapeutics (NASDAQ:SAGE) last released its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported ($1.53) EPS for the quarter, missing analysts’ consensus estimates of ($1.52) by ($0.01). The firm had revenue of $11.87 million during the quarter, compared to the consensus estimate of $10.80 million. Sage Therapeutics had a negative net margin of 317.29% and a negative return on equity of 50.29%. Sage Therapeutics’s quarterly revenue was up 337.1% on a year-over-year basis. During the same quarter in the prior year, the company earned ($2.81) EPS. Analysts predict that Sage Therapeutics will post -6.53 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Sage Therapeutics

Several large investors have recently modified their holdings of SAGE. State Street Corp grew its stake in Sage Therapeutics by 18.2% in the 3rd quarter. State Street Corp now owns 2,926,239 shares of the biopharmaceutical company’s stock valued at $21,127,000 after buying an additional 451,377 shares during the last quarter. RTW Investments LP increased its stake in shares of Sage Therapeutics by 2.0% during the third quarter. RTW Investments LP now owns 5,591,700 shares of the biopharmaceutical company’s stock worth $40,372,000 after purchasing an additional 111,123 shares during the period. Federated Hermes Inc. acquired a new stake in Sage Therapeutics during the 2nd quarter worth approximately $7,281,000. Charles Schwab Investment Management Inc. boosted its stake in Sage Therapeutics by 10.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 452,193 shares of the biopharmaceutical company’s stock valued at $3,265,000 after purchasing an additional 43,617 shares during the period. Finally, Renaissance Technologies LLC grew its holdings in Sage Therapeutics by 1,476.6% in the 2nd quarter. Renaissance Technologies LLC now owns 553,396 shares of the biopharmaceutical company’s stock valued at $6,010,000 after buying an additional 518,296 shares in the last quarter. 99.22% of the stock is owned by institutional investors.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.